CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc.

芝加哥--（商业新闻短讯）--Xeris Biopharma Holdings，Inc.（纳斯达克：XERS），一家以增长为导向的生物制药公司，致力于通过开发和商业化各种疗法的创新产品来改善患者的生活，今天宣布，它已与Beta Bionics，Inc.签订了独家全球合作和许可协议。

for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems..

用于开发和商业化胰高血糖素产品，利用Xeris的Xerosol™技术用于Beta Bionics专有的双激素泵和泵系统。。

“We’re excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes,” said Paul R. Edick, Chairman and CEO of Xeris. “We will move quickly to support Beta Bionics in this important development program.”.

Xeris董事长兼首席执行官Paul R.Edick表示：“作为胰高血糖素成分的独家供应商，我们很高兴与Beta Bionics合作，这将有助于他们为糖尿病患者开发首款双激素泵。我们将迅速采取行动，在这一重要的开发计划中支持Beta Bionics。”。

“If insulin is like the gas pedal in your car, then glucagon is the brakes,” said Sean Saint, CEO of Beta Bionics. “Beta Bionics has always felt that a bi-hormonal glucose control system has real advantages over insulin alone…just like the brakes in your car. Now with this partnership with Xeris, we are ready to take the next step in bringing this system to market.”.

贝塔仿生公司首席执行官肖恩·圣特说：“如果胰岛素就像汽车的油门踏板，那么胰高血糖素就是刹车。”。“Beta Bionics一直认为，双激素血糖控制系统比单独使用胰岛素具有真正的优势……就像汽车的刹车一样。现在，通过与Xeris的合作，我们准备采取下一步将该系统推向市场。”。

Under the terms of the License Agreement, Xeris has the potential to receive development payments, plus low double-digit royalties based on future sales of the Xeris glucagon for pumps and pump systems.

根据许可协议的条款，Xeris有可能获得开发费用，以及基于Xeris胰高血糖素泵和泵系统未来销售的两位数低版税。

About Xeris

任务

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, for a proven therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome.

Xeris（纳斯达克股票代码：XERS）是一家以增长为导向的生物制药公司，致力于通过开发和商业化各种疗法的创新产品来改善患者的生活。Xeris有三种市售产品；Gvoke®是一种用于治疗严重低血糖的即用液体胰高血糖素，Keveyis®用于治疗原发性周期性麻痹，Recorlev®用于治疗内源性库欣综合征。

Xeris also has a pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect®, supporting long-term product development and commercial success..

Xeris还拥有一系列开发计划，将当前上市的产品扩展到重要的新适应症和用途，并使用其专有配方技术平台XeriSol™和XeriJect®推出新产品，支持长期产品开发和商业成功。。

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

施乐生物制药控股公司总部位于伊利诺伊州芝加哥。有关更多信息，请访问www.xerispharma.com，或通过X、LinkedIn或Instagram关注我们。

About Beta Bionics

关于Beta仿生学

Beta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the single hormone and bi-hormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control, relieving some of the burden of living with diabetes.

Beta Bionics是一家医疗技术公司，专注于其单激素和双激素配置的回肠仿生胰腺的设计，开发和商业化。iLet仿生胰腺平台旨在使用自适应，自学习，控制算法，以及连续血糖监测和泵技术，自主计算和管理胰岛素和/或胰高血糖素的剂量，并模仿身体维持严格血糖控制的自然能力，减轻糖尿病患者的一些负担。

To learn more, visit www.betabionics.com..

To learn more, visit www.betabionics.com..

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.

Beta Bionics是一家营利性、公益性公司和认证B公司。自2015年成立以来，其使命一直是帮助改善患有糖尿病和其他血糖失调的儿童和成人的健康状况和生活质量。

Forward-Looking Statements

前瞻性声明

Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development and potential of a glucagon product utilizing Xeris’ XeriSol™ technology, the expectations regarding future product development efforts between Xeris and Beta Bionics, Xeris’ potential entitlements to milestone and royalty payments from Beta Bionics, the potential utility of its formulation platforms such as XeriSol™, the market and therapeutic potential of its products and product candidates, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中除历史事实声明外的任何声明均为前瞻性声明。前瞻性陈述包括但不限于关于Xeris Biopharma Holdings，Inc.未来预期、计划和前景的陈述，包括利用Xeris‘XeriSol™技术的胰高血糖素产品的开发和潜力，关于Xeris和Beta Bionics之间未来产品开发努力的期望，Xeris从Beta Bionics获得里程碑和特许权使用费的潜在权利，Xeris™等配方平台的潜在效用，其产品和候选产品的市场和治疗潜力，以及其他包含“将”、“将”、“继续”、“期望”、“应该”、“预期”和类似表述的陈述，构成了1995年《私人证券诉讼改革法案》含义内的前瞻性陈述。（笑声）。

These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate.

这些前瞻性陈述基于众多假设和评估，这些假设和评估是根据Xeris的经验和对历史趋势、当前状况、业务战略、运营环境、未来发展、地缘政治因素和其他其认为合适的因素的看法做出的。

By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether.

就其性质而言，前瞻性陈述涉及已知和未知的风险和不确定性，因为它们与事件有关，并取决于未来将发生的情况。可能导致Xeris的实际业绩、业绩或成就、行业业绩和发展与此类前瞻性声明中表达或暗示的结果、业绩或成就、行业业绩和发展存在重大差异的各种因素包括但不限于其财务状况和融资需求，包括为其产品开发计划或商业化努力提供资金，无论是否。